Cronos Group Inc. Common Share (CRON) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $3.30 (-1.79% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRON ranks #285 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±5.3% realized swing band)
SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($149.0K FCF) & 42.8% Gross Margin
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CRON currently carries a cautious 51/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.30) and Max Pain ($3.47) forces dealer call-delta covering toward $3.79.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cronos Group Inc. Common Share (CRON) slipped -1.79% to $3.30, trading at 77% of its 52-week range ($2.28 – $3.61). Stretched risk/reward at current multiples (-5% return on capital) under elevated 10-year interest-rate pressure.
Oil prices still reflect a war premium, with supply risks and depleted buffers keeping energy costs elevated. That kind of backdrop often punishes weaker balance sheets and rewards sturdier ones. For Canadian penny stock
Altria owns 42.5% of Cronos Group and 8.1% of AB InBev, providing a lower-risk backdoor play. A 5.9% dividend yield pays you to wait, but longer-dated calls might be better than the unusually active Nov. 20 calls.
With the Bank of Canada lifting its key interest rate and signaling that borrowing costs could rise further, cash now earns more and weak balance sheets matter more. That puts financially healthier penny stocks in a very
AI is soaking up massive amounts of capital right now, with Meta’s recent US$25 billion share sale reportedly drawing demand about five times larger than the deal size. That kind of appetite for growth stories can pull a
Energy prices are back in the spotlight as the Bank of Canada signals a possible rate hike to keep fuel driven inflation from spilling into everything from groceries to rent. Higher borrowing costs can punish heavily ind
Here is how Cronos Group (CRON) and Amgen (AMGN) have performed compared to their sector so far this year.
Rising global interest rates have made borrowing more expensive and pushed many investors toward safer balance sheets. That shift puts a spotlight on Canadian penny stocks that pair low share prices with relatively stron
Cronos (CRON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Canadian small caps suddenly look more interesting after the Federal Reserve paused rate hikes, giving global markets a bit more breathing room. Cheaper funding and a calmer backdrop can matter a lot more to tiny, well r
Food inflation is pressuring household budgets worldwide, and that makes every dollar of investment capital matter more. Canadian penny stocks with healthier finances can offer exposure to early-stage growth stories with
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +24.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRON today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRON. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cronos Group Inc. Common Share (CRON) ranks #285 by composite RQD confidence (51/100, grade D) and #334 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, CRON leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CRON at 51/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRON
ACTIVE
Cronos Group Inc. Common Share | D | 51/100 | — | 42.8% | -4.5% | -1.79% | $1.24B | Benchmark Subject |
| TRLV Trulieve Cannabis Corp. Subordinate Voting Shares | D+ | 58/100 | — | 60.2% | 12.8% | -3.02% | $2.04B | /trlv-vs-cron → |
| RGC Regencell Bioscience Holdings Limited | D- | 38/100 | — | — | — | -2.19% | $3.40B | /rgc-vs-cron → |
| TLRY Tilray Brands Inc. | E | 20/100 | — | 28.4% | -3.9% | -4.17% | $390.2M | /tlry-vs-cron → |
| OBIO Orchestra BioMed Holdings Inc. | D- | 36/100 | — | 96.0% | -35.0% | -2.96% | $366.0M | /obio-vs-cron → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cronos Group Inc. Common Share (CRON) reported GAAP revenue of $146.6M (+24.6% vs. FY2024 revenue of $117.6M , and +68.0% cumulative change since FY2023) , GAAP net income of -$2.9M, operating cash flow of $25.9M, and free cash flow of $149.0K (-97.7% YoY). On the balance sheet, CRON closed FY2025 with $1.20B in total assets against $0 in total debt (Altman Z-Score: 15.20, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $146.6M | -$2.9M | $25.9M | $149.0K | $1.20B | — |
| FY2024 (FY) | 2024-12-31 | $117.6M | $40.0M | $18.8M | $6.4M | $1.17B | — |
| FY2023 (FY) | 2023-12-31 | $87.2M | -$73.9M | -$42.8M | -$42.8M | — | — |
As of 2026-11-02, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $3.30 (-1.79% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRON ranks #285 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRON last traded at $3.30 (-1.79% on volume of 1,091,082 shares), positioning the stock 0.00% above its 50-day simple moving average ($3.30) and +15.38% above its 200-day simple moving average ($2.86). Across its 52-week range of $2.28 to $3.61, CRON sits at the 76.7% percentile with a 14-day RSI of 55.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.3% ($3.13 to $3.47).
Why CRON Stock slipped -1.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-5% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CRON carries an RQD Score of 51 and a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC -4.5%; FCF yield 0.01%), Whale 13F Flow at 13/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 15.2; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is insider conviction, and the cash engine is also weak given negative ROIC and a near-zero FCF yield. The balance-sheet pillar is comparatively stronger on the forensic metrics provided. For a prospective investor, the rating points to limited earnings-based upside support today, with the strongest supportive evidence coming from the balance-sheet and institutional-flow pillars rather than from operating returns. Valuation tradeoffs cannot be assessed precisely because P/E and EV/EBITDA are not available in source data.
Cronos Group Inc. Common Share (CRON) is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry, per the company profile. The profile does not describe its specific products, customers, or revenue model. Per the SEC financials, the company reported revenue of $146.6M for FY 2025. Beyond sector, industry, and exchange, further business detail is not available in source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $146.6M | $-17.4M | $-2.9M | N/A | $0.1M | $791.8M | N/A |
| FY 2024 | $117.6M | $-76.5M | $40.0M | N/A | $6.4M | $858.8M | N/A |
| FY 2023 | $87.2M | $-84.8M | $-73.9M | N/A | $-42.8M | N/A | N/A |
Per the SEC financials, revenue grew from $87.2M in FY 2023 to $146.6M in FY 2025, while operating income remained negative in all three periods. Per the market data, the gross margin is 42.8%, the operating margin is -11.9%, and the net margin is -2%, with ROIC at -4.5%. Per the Roarable RQD rating, the Altman Z-Score is 15.2 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. Reported cash was $791.8M at FY 2025, down from $858.8M at FY 2024.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from source data. The only sector-level context available is the Health Care classification and the Medicinal Chemicals and Botanical Products industry, with a beta of 1.0 per the market data.
Real-time company headlines, analyst actions, and sector developments for Cronos Group Inc. Common Share (CRON) • Click "Debate This Headline" to argue it in the Roar Pit below
Oil prices still reflect a war premium, with supply risks and depleted buffers keeping energy costs elevated. That kind of backdrop often punishes weaker balance sheets and rewards sturdier ones. For Canadian penny stock
Altria owns 42.5% of Cronos Group and 8.1% of AB InBev, providing a lower-risk backdoor play. A 5.9% dividend yield pays you to wait, but longer-dated calls might be better than the unusually active Nov. 20 calls.
With the Bank of Canada lifting its key interest rate and signaling that borrowing costs could rise further, cash now earns more and weak balance sheets matter more. That puts financially healthier penny stocks in a very
AI is soaking up massive amounts of capital right now, with Meta’s recent US$25 billion share sale reportedly drawing demand about five times larger than the deal size. That kind of appetite for growth stories can pull a
Energy prices are back in the spotlight as the Bank of Canada signals a possible rate hike to keep fuel driven inflation from spilling into everything from groceries to rent. Higher borrowing costs can punish heavily ind
Here is how Cronos Group (CRON) and Amgen (AMGN) have performed compared to their sector so far this year.
Rising global interest rates have made borrowing more expensive and pushed many investors toward safer balance sheets. That shift puts a spotlight on Canadian penny stocks that pair low share prices with relatively stron
Cronos (CRON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Welcome to the CRON (Cronos Group Inc. Common Share) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CRON, but look at what you are paying: current EV/EBITDA multiples with 42.8% gross margins. Unless Cronos Group Inc. Common Share expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CRON, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $3.36 (52-wk range $2.28 - $3.61), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).